{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:17:28Z","timestamp":1785525448299,"version":"3.56.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The signaling pathways of growth factors, including platelet-derived growth factor, can be considered specific targets for overcoming the poor prognosis of idiopathic pulmonary fibrosis. Nintedanib, the recently approved multiple kinase inhibitor, has shown promising antifibrotic effects in patients with idiopathic pulmonary fibrosis; however, its efficacy is still limited, and in some cases, treatment discontinuation is necessary owing to toxicities such as gastrointestinal disorders. Therefore, more effective agents with less toxicity are still needed. TAS-115 is a novel multiple tyrosine kinase inhibitor that preferably targets platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor, and c-FMS in addition to other molecules. In this study, we evaluated the antifibrotic effect of TAS-115 on pulmonary fibrosis in vitro and in vivo. TAS-115 inhibited the phosphorylation of PDGFR on human lung fibroblast cell line MRC-5 cells and suppressed their platelet-derived growth factor\u2013induced proliferation and migration. Furthermore, TAS-115 inhibited the phosphorylation of c-FMS, a receptor of macrophage colony-stimulating factor, in murine bone marrow\u2013derived macrophages and decreased the production of CCL2, another key molecule for inducing pulmonary fibrosis, under the stimulation of macrophage colony-stimulating factor. Importantly, the inhibitory effects of TAS-115 on both PDGFR and c-FMS were 3- to 10-fold higher than those of nintedanib. In a mouse model of bleomycin-induced pulmonary fibrosis, TAS-115 significantly inhibited the development of pulmonary fibrosis and the collagen deposition in bleomycin-treated lungs. These data suggest that strong inhibition of PDGFR and c-FMS by TAS-115 may be a promising strategy for overcoming the intractable pathogenesis of pulmonary fibrosis.<\/jats:p>","DOI":"10.1165\/rcmb.2018-0098oc","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T17:10:19Z","timestamp":1544634619000},"page":"478-487","source":"Crossref","is-referenced-by-count":24,"title":["The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice"],"prefix":"10.1093","volume":"60","author":[{"given":"Kazuya","family":"Koyama","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology and"},{"name":"Department of Respiratory Medicine, Toho University Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatsugu","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Morizumi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seidai","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Molecular and Environmental Pathology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakae","family":"Homma","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Toho University Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"key":"2026012222072961200_bib1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012222072961200_bib2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1165\/rcmb.2013-0455OC","article-title":"Role of platelet-derived growth factor\/platelet-derived growth factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis","volume":"51","author":"Aono","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012222072961200_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2152\/jmi.60.175","article-title":"Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis","volume":"60","author":"Nishioka","year":"2013","journal-title":"J Med Invest"},{"key":"2026012222072961200_bib4","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/rccm.200404-531OC","article-title":"Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice","volume":"171","author":"Aono","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012222072961200_bib5","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1164\/rccm.200702-178OC","article-title":"Role of \u03b11-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice","volume":"176","author":"Azuma","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012222072961200_bib6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1164\/rccm.200906-0964OC","article-title":"Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results","volume":"181","author":"Daniels","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012222072961200_bib7","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012222072961200_bib8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1124\/jpet.117.244129","article-title":"The triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases","volume":"364","author":"Hilberg","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"2026012222072961200_bib9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12885-017-3324-3","article-title":"Therapeutic potential of TAS-115 via c-MET and PDGFR\u03b1 signal inhibition for synovial sarcoma","volume":"17","author":"Yamada","year":"2017","journal-title":"BMC Cancer"},{"key":"2026012222072961200_bib10","doi-asserted-by":"crossref","first-page":"e0164830","DOI":"10.1371\/journal.pone.0164830","article-title":"High potency VEGFRs\/MET\/FMS triple blockade by TAS-115 concomitantly suppresses tumor progression and bone destruction in tumor-induced bone disease model with lung carcinoma cells","volume":"11","author":"Fujita","year":"2016","journal-title":"PLoS One"},{"key":"2026012222072961200_bib11","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res"},{"key":"2026012222072961200_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1164\/rccm.200609-1279OC","article-title":"Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis","volume":"176","author":"Baran","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012222072961200_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-pathol-012513-104706","article-title":"Pathogenesis of idiopathic pulmonary fibrosis","volume":"9","author":"Wolters","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"2026012222072961200_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI111953","article-title":"Rat lung fibroblast collagen metabolism in bleomycin-induced pulmonary fibrosis","volume":"76","author":"Phan","year":"1985","journal-title":"J Clin Invest"},{"key":"2026012222072961200_bib15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1349-7006.2003.tb01437.x","article-title":"Soluble Fas in malignant pleural effusion and its expression in lung cancer cells","volume":"94","author":"Mitani","year":"2003","journal-title":"Cancer Sci"},{"key":"2026012222072961200_bib16","doi-asserted-by":"crossref","first-page":"8792","DOI":"10.1038\/ncomms9792","article-title":"Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab","volume":"6","author":"Mitsuhashi","year":"2015","journal-title":"Nat Commun"},{"key":"2026012222072961200_bib17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jcp.41.4.467","article-title":"Simple method of estimating severity of pulmonary fibrosis on a numerical scale","volume":"41","author":"Ashcroft","year":"1988","journal-title":"J Clin Pathol"},{"key":"2026012222072961200_bib18","doi-asserted-by":"crossref","first-page":"20891","DOI":"10.1074\/jbc.M116.727875","article-title":"The MET\/vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitor also attenuates fms-dependent osteoclast differentiation and bone destruction induced by prostate cancer","volume":"291","author":"Watanabe","year":"2016","journal-title":"J Biol Chem"},{"key":"2026012222072961200_bib19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3389\/fmicb.2017.00587","article-title":"C-C motif chemokine ligand 2 (CCL2) mediates acute lung injury induced by lethal influenza H7N9 virus","volume":"8","author":"Lai","year":"2017","journal-title":"Front Microbiol"},{"key":"2026012222072961200_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1755-1536-4-23","article-title":"Chemokine (C-C motif) ligand 2 mediates direct and indirect fibrotic responses in human and murine cultured fibrocytes","volume":"4","author":"Ekert","year":"2011","journal-title":"Fibrogenesis Tissue Repair"},{"key":"2026012222072961200_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1165\/rcmb.2005-0253OC","article-title":"The CC chemokine ligand 2 (CCL2) mediates fibroblast survival through IL-6","volume":"37","author":"Liu","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012222072961200_bib22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0002-9440(10)62289-4","article-title":"CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury","volume":"166","author":"Moore","year":"2005","journal-title":"Am J Pathol"},{"key":"2026012222072961200_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1465-9921-15-16","article-title":"Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis","volume":"15","author":"Inomata","year":"2014","journal-title":"Respir Res"},{"key":"2026012222072961200_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"2026012222072961200_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12890-017-0405-7","article-title":"Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2\/Bach1 equilibrium","volume":"17","author":"Liu","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2026012222072961200_bib26","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1111\/jcmm.13206","article-title":"Nintedanib reduces ventilation-augmented bleomycin-induced epithelial-mesenchymal transition and lung fibrosis through suppression of the Src pathway","volume":"21","author":"Li","year":"2017","journal-title":"J Cell Mol Med"},{"key":"2026012222072961200_bib27","first-page":"89","article-title":"Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis","volume":"10","author":"Inomata","year":"2015","journal-title":"Core Evid"},{"key":"2026012222072961200_bib28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0002-9440(10)65115-2","article-title":"Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats","volume":"155","author":"Rice","year":"1999","journal-title":"Am J Pathol"},{"key":"2026012222072961200_bib29","doi-asserted-by":"crossref","first-page":"170061","DOI":"10.1183\/16000617.0061-2017","article-title":"Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease","volume":"26","author":"Kanaan","year":"2017","journal-title":"Eur Respir Rev"},{"key":"2026012222072961200_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.intimp.2008.10.002","article-title":"VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice","volume":"9","author":"Ou","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"2026012222072961200_bib31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nm.4035","article-title":"Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis","volume":"22","author":"Cao","year":"2016","journal-title":"Nat Med"},{"key":"2026012222072961200_bib32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1164\/rccm.201603-0568OC","article-title":"Differential expression of VEGF-Axxx isoforms is critical for development of pulmonary fibrosis","volume":"196","author":"Barratt","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012222072961200_bib33","doi-asserted-by":"crossref","first-page":"92192","DOI":"10.1172\/jci.insight.92192","article-title":"Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis","volume":"2","author":"Murray","year":"2017","journal-title":"JCI Insight"},{"key":"2026012222072961200_bib34","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1096\/fasebj.1.6.3315806","article-title":"Fibroblast growth factors","volume":"1","author":"Thomas","year":"1987","journal-title":"FASEB J"},{"key":"2026012222072961200_bib35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/path.4768","article-title":"Fibroblast growth factor-1 attenuates TGF-\u03b21-induced lung fibrosis","volume":"240","author":"Shimbori","year":"2016","journal-title":"J Pathol"},{"key":"2026012222072961200_bib36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1165\/rcmb.2014-0184OC","article-title":"Fibroblast growth factor 2 is required for epithelial recovery, but not for pulmonary fibrosis, in response to bleomycin","volume":"52","author":"Guzy","year":"2015","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012222072961200_bib37","first-page":"A4028","article-title":"Effect of blockade of fibroblast growth factor receptor signaling in experimental pulmonary fibrosis in mice [abstract]","volume":"193","author":"Sato","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012222072961200_bib38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/path.4825","article-title":"Fibroblast growth factors and pulmonary fibrosis: it\u2019s more complex than it sounds","volume":"241","author":"Kim","year":"2017","journal-title":"J Pathol"},{"key":"2026012222072961200_bib39","doi-asserted-by":"crossref","first-page":"L615","DOI":"10.1152\/ajplung.00185.2015","article-title":"FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro","volume":"310","author":"Joannes","year":"2016","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026012222072961200_bib40","first-page":"A2397","article-title":"Nintedanib attenuates the polarization of profibrotic macrophages through the inhibition of tyrosine phosphorylation on CSF1 receptor [abstract]","volume":"195","author":"Tandon","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012222072961200_bib41","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1535-7163.MCT-13-0459","article-title":"The novel VEGF receptor\/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile","volume":"12","author":"Fujita","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"2026012222072961200_bib42","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1164\/ajrccm.162.6.9908097","article-title":"Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis","volume":"162","author":"Dohi","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012222072961200_bib43","doi-asserted-by":"crossref","first-page":"L529","DOI":"10.1152\/ajplung.00082.2006","article-title":"Gene transfer of hepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis","volume":"292","author":"Gazdhar","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026012222072961200_bib44","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1096\/fj.04-1535fje","article-title":"HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis","volume":"19","author":"Mizuno","year":"2005","journal-title":"FASEB J"},{"key":"2026012222072961200_bib45","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1164\/ajrccm.156.6.9611057","article-title":"Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin: a morphologic study","volume":"156","author":"Yaekashiwa","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012222072961200_bib46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000318854","article-title":"Simultaneous stimulation with TGF-\u03b21 and TNF-\u03b1 induces epithelial mesenchymal transition in bronchial epithelial cells","volume":"155","author":"Kamitani","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"key":"2026012222072961200_bib47","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1165\/rcmb.2004-0288OC","article-title":"Tumor necrosis factor-\u03b1 induces transforming growth factor-\u03b21 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway","volume":"32","author":"Sullivan","year":"2005","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012222072961200_bib48","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/jco.2015.33.15_suppl.2532","article-title":"First-in-human study of TAS-115, a novel oral MET\/VEGFR inhibitor, in patients with advanced solid tumors","volume":"33","author":"Matsubara","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Respiratory Cell and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article-pdf\/60\/4\/478\/66465720\/ajrcmb_60_4_478.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article-pdf\/60\/4\/478\/66465720\/ajrcmb_60_4_478.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T03:12:10Z","timestamp":1769137930000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article\/60\/4\/478\/8430434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,1]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1165\/rcmb.2018-0098oc","relation":{},"ISSN":["1044-1549","1535-4989"],"issn-type":[{"value":"1044-1549","type":"print"},{"value":"1535-4989","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2019,4,1]]}}}